These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26672604)

  • 21. Hematology consult: high-sensitivity warfarin genotype.
    Schwer C; Lamana S; Dasanu CA
    Conn Med; 2013; 77(10):581-5. PubMed ID: 24367840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation.
    Zhu Y; You J; Gu X; Zhu H; Liu J
    Eur J Clin Pharmacol; 2023 Mar; 79(3):427-435. PubMed ID: 36708395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis.
    Belley-Cote EP; Hanif H; D'Aragon F; Eikelboom JW; Anderson JL; Borgman M; Jonas DE; Kimmel SE; Manolopoulos VG; Baranova E; Maitland-van der Zee AH; Pirmohamed M; Whitlock RP
    Thromb Haemost; 2015 Oct; 114(4):768-77. PubMed ID: 26158747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomics and warfarin therapy.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
    Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
    Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal loading dose of warfarin for the initiation of oral anticoagulation.
    Mahtani KR; Heneghan CJ; Nunan D; Bankhead C; Keeling D; Ward AM; Harrison SE; Roberts NW; Hobbs FD; Perera R
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD008685. PubMed ID: 23235665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis.
    Lam J; Schulman S; Witt DM; Vandvik PO; Qayyum F; Holbrook AM
    Pharmacotherapy; 2013 Nov; 33(11):1184-90. PubMed ID: 23744743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of warfarin in paediatric patients with prosthetic cardiac valves: a retrospective audit.
    Wong CS; Batchelor K; Bua J; Newall F
    Thromb Res; 2011 Oct; 128(4):331-4. PubMed ID: 21620442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring.
    Simmons BJ; Jenner KM; Delate T; Clark NP; Kurz D; Witt DM
    Pharmacotherapy; 2012 Dec; 32(12):1078-84. PubMed ID: 23112110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
    Larson BJ; Zumberg MS; Kitchens CS
    Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
    Anthony CJ; Karim S; Ackroyd-Stolarz S; Fry A; Murphy NG; Christie R; Zed PJ
    Ann Pharmacother; 2011 Jul; 45(7-8):881-7. PubMed ID: 21750309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed-dose versus adjusted-dose warfarin in patients with prosthetic heart valves in a peri-urban impoverished population.
    Buchanan-Leel B; Levetan BN; Lombard CJ; Commerford PJ
    J Heart Valve Dis; 2002 Jul; 11(4):583-92; discussion 593. PubMed ID: 12150309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin.
    Vijenthira A; Le Gal G; Castellucci LA; Carrier M
    Thromb Res; 2014 Sep; 134(3):584-6. PubMed ID: 25037497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
    Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
    Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
    McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
    Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.
    Guo C; Kuang Y; Zhou H; Yuan H; Pei Q; Li J; Jiang W; Ng CM; Chen X; Huo Y; Cui Y; Wang X; Yu J; Sun X; Yu W; Chen P; Miao D; Liu W; Yu Z; Ouyang Z; Shi X; Lv C; Peng Z; Xiong G; Zeng G; Zeng J; Dai H; Peng J; Zhang Y; Xu F; Wu J; Chen X; Gong H; Yang Z; Wu X; Fang Q; Yang L; Li H; Tan H; Huang Z; Tang X; Yang Q; Tu S; Wang X; Xiang Y; Huang J; Wang X; Cai J; Jiang S; Huang L; Peng J; Gong L; Zou C; Yang G
    Circ Genom Precis Med; 2020 Aug; 13(4):e002602. PubMed ID: 32510984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial.
    Majeed H; Rodger M; Forgie M; Carrier M; Taljaard M; Scarvelis D; Gonsalves C; Rodriguez RA; Wells PS
    Thromb Res; 2013 Sep; 132(3):329-35. PubMed ID: 23953594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.